Omeros Corp
OMER6.590USD
+0.010+0.15%
Cierre 11/07, 16:00（ET）Cotizaciones retrasadas 15 min
395.55MCap. mercado
PérdidaP/E TTM
Más Datos de Omeros Corp Compañía
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Información de Omeros Corp
Símbolo de cotizaciónOMER
Nombre de la empresaOmeros Corp
Fecha de salida a bolsaOct 08, 2009
Director ejecutivoDR. Gregory A. Demopulos, M.D.
Número de empleados202
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 08
Dirección201 Elliott Avenue West
CiudadSEATTLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal98119
Teléfono12066765000
Sitio Webhttps://www.omeros.com/
Símbolo de cotizaciónOMER
Fecha de salida a bolsaOct 08, 2009
Director ejecutivoDR. Gregory A. Demopulos, M.D.
Ejecutivos de Omeros Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 8 de nov
Actualizado: sáb., 8 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Ingalls & Snyder LLC (Asset Management)
6.03%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.92%
D. E. Shaw & Co., L.P.
2.42%
Stifel, Nicolaus & Company, Incorporated
2.24%
Otro
78.96%
Accionistas
Accionistas
Proporción
Ingalls & Snyder LLC (Asset Management)
6.03%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.92%
D. E. Shaw & Co., L.P.
2.42%
Stifel, Nicolaus & Company, Incorporated
2.24%
Otro
78.96%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
16.48%
Investment Advisor
15.58%
Hedge Fund
6.07%
Research Firm
3.82%
Individual Investor
2.90%
Bank and Trust
0.88%
Insurance Company
0.12%
Venture Capital
0.09%
Pension Fund
0.05%
Otro
53.99%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
243
29.83M
43.83%
+1.23M
2025Q2
255
30.16M
44.94%
-422.08K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Ingalls & Snyder LLC (Asset Management)
3.98M
5.85%
+5.10K
+0.13%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.69M
5.43%
-328.94K
-8.18%
Jun 30, 2025
The Vanguard Group, Inc.
3.28M
4.82%
+46.32K
+1.43%
Jun 30, 2025
D. E. Shaw & Co., L.P.
1.65M
2.42%
-291.10K
-15.02%
Jun 30, 2025
Stifel, Nicolaus & Company, Incorporated
1.52M
2.24%
-33.76K
-2.17%
Jun 30, 2025
Demopulos (Gregory A. M.D.)
2.03M
2.98%
--
--
May 23, 2025
Geode Capital Management, L.L.C.
1.37M
2.01%
+739.00
+0.05%
Jun 30, 2025
State Street Investment Management (US)
1.20M
1.76%
-156.01K
-11.50%
Jun 30, 2025
Two Sigma Investments, LP
1.09M
1.61%
+971.88K
+802.28%
Jun 30, 2025
Morgan Stanley & Co. LLC
1.09M
1.6%
+501.25K
+85.73%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.48%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.48%
iShares Micro-Cap ETF
Proporción0.05%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
ProShares UltraPro Russell2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
